{"id":1748,"date":"2003-10-01T01:00:00","date_gmt":"2003-10-01T00:00:00","guid":{"rendered":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/"},"modified":"2018-10-20T18:39:30","modified_gmt":"2018-10-20T16:39:30","slug":"traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe","status":"publish","type":"post","link":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/","title":{"rendered":"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re."},"content":{"rendered":"<p><strong>2003<\/strong><\/p>\n<p><em>Bruno Bour (1), Elisabeth Tocqu\u00e9 (2), Jean-Luc Staub (3), Olivier Nouel (4), Michel Chousterman (5), Denis Labayle (6), Bernard Nalet (7), Alexandre Pariente (8), Sylvie Bonnot-Marlier (2), ANGH<br \/>\n(1) CH Le Mans, (2) Laboratoires Janssen-Cilag, (3) CH Niort, (4) CH Saint Brieuc, (5) CH Intercommunal Cr\u00e9teil, (6) CH Evry, (7) CH Mont\u00e9limar, (8) CH Pau<\/em><\/p>\n<p><strong>Gastroent\u00e9rologie <\/strong>&#8211; \u00a02003-05-28 &#8211;\u00a0CO &#8211;<\/p>\n<p>________________________________<\/p>\n<p>Introduction : Le RGO clinique avec ou sans oesophagite mod\u00e9r\u00e9e est fr\u00e9quent. Dans ces cas le traitement par IPP en continu est recommand\u00e9 en cas de sympt\u00f4mes fr\u00e9quents et r\u00e9cidivants (1). Le Rab est un inhibiteur de la pompe \u00e0 proton (IPP) d\u2019action de d\u00e9but rapide et de dur\u00e9e prolong\u00e9e n\u2019ayant pas d\u2019interaction m\u00e9dicamenteuse. Il pourrait \u00eatre un candidat au traitement \u00e0 la demande des sympt\u00f4mes de ces malades.<br \/>\nBut : Evaluer l\u2019efficacit\u00e9 du traitement \u00e0 la demande par Rab 10mg dans une population de patients porteurs d\u2019un RGO sans l\u00e9sion endoscopique s\u00e9v\u00e8re mais alt\u00e9rant la qualit\u00e9 de vie par son caract\u00e8re r\u00e9cidivant.<br \/>\nM\u00e9thodes : Des patients porteurs de sympt\u00f4mes typiques (pyrosis et r\u00e9gurgitations) de RGO sans \u0153sophagite ou avec \u0153sophagite \u00e9rosive mod\u00e9r\u00e9e (grades 1 ou 2 de Savary-Miller) ont \u00e9t\u00e9 inclus dans une \u00e9tude ouverte et pragmatique. Les sympt\u00f4mes \u00e9taient mod\u00e9r\u00e9s \u00e0 s\u00e9v\u00e8res (score de Likert &gt; 2 \u2013 sur une \u00e9chelle de 5) et avaient n\u00e9cessit\u00e9 au moins 3 cures de traitement antis\u00e9cr\u00e9toire efficaces dans l\u2019ann\u00e9e pr\u00e9c\u00e9dant l\u2019inclusion. Apr\u00e8s 4 semaines de traitement par Rab 10mg per os, les patients ayant r\u00e9pondu \u00e0 ce traitement (Likert \u00a3 2) \u00e9taient randomis\u00e9s pour recevoir un traitement par Rab 10 mg en continu (TC) ou \u00e0 la demande (TAD) pendant 6 mois. Le traitement \u00e0 la demande consistait en une reprise de Rab devant la r\u00e9apparition des m\u00eames sympt\u00f4mes et pendant les 2 jours suivant leur disparition. Les patients rechuteurs (r\u00e9cidive des sympt\u00f4mes initiaux de m\u00eame intensit\u00e9 pendant plus de 7 jours) \u00e9taient exclus de l\u2019\u00e9tude. A la fin du 6\u00b0 mois, l\u2018\u00e9valuation \u00e9tait faite sur le pourcentage de patients satisfaits (Likert \u00a3 2).<br \/>\nR\u00e9sultats : Sur les 176 patients inclus (hommes, 53% ; age moyen, 49 ans ; RGO sans oesophagite, 36,4% ; RGO avec \u0153sophagite grade 1, 53,4% ; RGO avec \u0153sophagite grade 2, 10,2%), 88,6% ont r\u00e9pondus aux 4 semaines de traitement par Rab. Cent cinquante deux patients ont \u00e9t\u00e9 randomis\u00e9es (TC, n=81 ; TAD, n=71).<br \/>\nApr\u00e8s 6 mois de traitement : 1-La disparition des sympt\u00f4mes (Likert \u00a3 2) \u00e9tait discr\u00e8tement plus \u00e9lev\u00e9e chez les patients du groupe TC vs groupe TAD: 86,4% vs 74,6% respectivement sans que cette diff\u00e9rence soit significative (p=0,065). 2-Le score de qualit\u00e9 de vie (Reflux-Qual) n\u2019\u00e9tait pas diff\u00e9rent dans les 2 groupes (groupe TC :0,55 ; groupe TAD : 0,60 p=0,3957). 3-La consommation moyenne de Rab \u00e9tait significativement plus faible dans le groupe TAD vs groupe TC (respectivement 0,31 comprim\u00e9 vs 0,96 comprim\u00e9 , p&lt;0,0001).<br \/>\nUn total de 15,1% de patients a \u00e9t\u00e9 exclus de l\u2019\u00e9tude ( TC, 12,3% ; TAD, 18,3%) : 5,3% effets secondaires (TC, 6,2% ; TAD, 4,2%) et 1,3% r\u00e9cidives (TC, 0% ; TAD, 1,4%).<br \/>\nConclusion : Le traitement \u00e0 la demande avec 10mg de rab\u00e9prazole repr\u00e9sente une alternative au traitement continu des patients ayant un RGO symptomatique peu s\u00e9v\u00e8re mais fr\u00e9quemment r\u00e9cidivant.<\/p>\n<p>1- Reflux gastro-oesophagien de l\u2019adulte : diagnostic et traitement. Gastroenterol Clin Biol 1999 ;23 :56-65<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2003 Bruno Bour (1), Elisabeth Tocqu\u00e9 (2), Jean-Luc Staub (3), Olivier Nouel (4), Michel Chousterman (5), Denis Labayle (6), Bernard Nalet (7), Alexandre Pariente (8), Sylvie Bonnot-Marlier (2), ANGH (1) CH Le Mans, (2) Laboratoires Janssen-Cilag, (3) CH Niort, (4) CH Saint Brieuc, (5) CH Intercommunal Cr\u00e9teil, (6) CH Evry, (7) CH Mont\u00e9limar, (8) CH [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[14],"class_list":["post-1748","post","type-post","status-publish","format-standard","hentry","category-gastroenterologie","tag-14"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re. - Abstracts des congr\u00e8s de l&#039;ANGH<\/title>\n<meta name=\"description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re. - Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"og:description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/\" \/>\n<meta property=\"og:site_name\" content=\"Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\" \/>\n<meta property=\"article:published_time\" content=\"2003-10-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-10-20T16:39:30+00:00\" \/>\n<meta name=\"author\" content=\"abstracts\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"abstracts\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/\"},\"author\":{\"name\":\"abstracts\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\"},\"headline\":\"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re.\",\"datePublished\":\"2003-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:39:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/\"},\"wordCount\":553,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"keywords\":[\"2003\"],\"articleSection\":[\"Gastroenterologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/\",\"url\":\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/\",\"name\":\"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re. - Abstracts des congr\u00e8s de l&#039;ANGH\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#website\"},\"datePublished\":\"2003-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:39:30+00:00\",\"description\":\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\",\"breadcrumb\":{\"@id\":\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/angh.net\/abstracts\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/angh.net\/abstracts\/#website\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"name\":\"Abstracts des congr\u00e8s de l&#039;ANGH\",\"description\":\"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003\",\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/angh.net\/abstracts\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\",\"name\":\"ANGH\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"contentUrl\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"width\":48,\"height\":18,\"caption\":\"ANGH\"},\"image\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\",\"name\":\"abstracts\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"caption\":\"abstracts\"},\"url\":\"https:\/\/angh.net\/abstracts\/author\/abstracts\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re. - Abstracts des congr\u00e8s de l&#039;ANGH","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/","og_locale":"fr_FR","og_type":"article","og_title":"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re. - Abstracts des congr\u00e8s de l&#039;ANGH","og_description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","og_url":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/","og_site_name":"Abstracts des congr\u00e8s de l&#039;ANGH","article_publisher":"https:\/\/www.facebook.com\/ANGH-2136322560030484\/","article_published_time":"2003-10-01T00:00:00+00:00","article_modified_time":"2018-10-20T16:39:30+00:00","author":"abstracts","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"abstracts","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/#article","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/"},"author":{"name":"abstracts","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1"},"headline":"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re.","datePublished":"2003-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:39:30+00:00","mainEntityOfPage":{"@id":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/"},"wordCount":553,"commentCount":0,"publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"keywords":["2003"],"articleSection":["Gastroenterologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/","url":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/","name":"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re. - Abstracts des congr\u00e8s de l&#039;ANGH","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/#website"},"datePublished":"2003-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:39:30+00:00","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","breadcrumb":{"@id":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/angh.net\/abstracts\/traitement-a-la-demande-par-rabeprazole-rab-10-mg-une-alternative-au-traitement-continu-du-reflux-gastro-oesophagien-rgo-peu-severe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/angh.net\/abstracts\/"},{"@type":"ListItem","position":2,"name":"Traitement \u00e0 la demande par Rab\u00e9prazole (Rab) 10 mg : Une alternative au traitement continu du reflux gastro-oesophagien (RGO) peu s\u00e9v\u00e8re."}]},{"@type":"WebSite","@id":"https:\/\/angh.net\/abstracts\/#website","url":"https:\/\/angh.net\/abstracts\/","name":"Abstracts des congr\u00e8s de l&#039;ANGH","description":"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003","publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angh.net\/abstracts\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/angh.net\/abstracts\/#organization","name":"ANGH","url":"https:\/\/angh.net\/abstracts\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/","url":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","contentUrl":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","width":48,"height":18,"caption":"ANGH"},"image":{"@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ANGH-2136322560030484\/"]},{"@type":"Person","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1","name":"abstracts","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","caption":"abstracts"},"url":"https:\/\/angh.net\/abstracts\/author\/abstracts\/"}]}},"_links":{"self":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/comments?post=1748"}],"version-history":[{"count":0,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1748\/revisions"}],"wp:attachment":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/media?parent=1748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/categories?post=1748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/tags?post=1748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}